Frank Scott Lieberman (Frank S Lieberman, Frank Lieberman)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 4

Top Topics

Cross Sectional

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Michal Nisnboym, Sarah R Vincze, Zujian Xiong, Chaim T Sneiderman, Rebecca A Raphael, Bo Li, Ambika P Jaswal, ReidAnn E Sever, Kathryn E Day, Joseph D LaToche, Lesley M Foley, Hanieh Karimi, T Kevin Hitchens, Sameer Agnihotri, Baoli Hu, Dhivyaa Rajasundaram, Carolyn J Anderson, Deborah T Blumenthal, Thomas M Pearce, Shikhar Uttam, Jessie R Nedrow, Ashok Panigrahy, Ian F Pollack, Frank Scott Lieberman, Jan Drappatz, Itay Raphael, Wilson B Edwards, Gary Kohanbash
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma. Cancer research communications 3 (7) (2023)
Frank Scott Lieberman
Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Research 6 (2017)